In recognition of National Diabetes Month and concurrent with the
launch of KidneyIntelX in the Veterans Health Administration health
system, Renalytix (NASDAQ: RNLX) (LSE: RENX) convened a
multidisciplinary panel to discuss advances in kidney health
through early-stage prognosis and intervention of chronic kidney
disease (CKD) in patients with type 2 diabetes. Clinical experts
shared patient case studies drawing from their experience adding
KidneyIntelX into clinical care. The KidneyIntelX enabled care
pathway being implemented in the Mount Sinai Health System is a
model that can be used in implementing the new Veterans Health
Administration CKD Directive and joint VA and Department of Defense
guideline, driving care earlier to prevent progression and kidney
failure. The panel event took place at The Institute for Defense
and Government Advancement (IDGA) VA Healthcare Summit on
Wednesday, October 27, 2021.
The panel, “Breakthrough Diagnostic Approach for
Type 2 Diabetes and Early-Stage Chronic Kidney Disease
(CKD): Today’s Precise Answer, Tomorrow’s Kidney Health,”
included renowned thought leaders who highlighted the importance of
early detection and intervention to promote long-term kidney health
and improve clinical outcomes in their type 2 diabetes
patients.
Commenting on the Summit discussion, panelists
said:
Michael J. Donovan, PhD, MD, Chief
Medical Officer at Renalytix: “This roundtable discussion
provided a unique opportunity for clinical experts to highlight the
impact of KidneyIntelX risk assessment on patient-specific
management decisions. Their remarks highlighted how KidneyIntelX
testing can help address the challenges they face when relying on
current clinical tools. The panel also reviewed the
practice-changing evidence from recent therapeutic trials. The
discussion underscored the importance of a systems approach to
managing care for chronic kidney disease patients given the
intimate association of cardiovascular and kidney function.”
David Lam, MD, Assistant Professor of
Medicine (Endocrinology, Diabetes and Bone Disease) at the Icahn
School of Medicine at Mount Sinai and Medical Director at the Mount
Sinai Clinical Diabetes Institute, NYC, NY: “As an
endocrinologist, I see patients living with diabetes day in and day
out. Diabetes care is a team effort. I co-manage diabetic patients
with other trained professionals, all working towards the care of
patients to help them thrive. KidneyIntelX has helped me to
identify patients with early-stage diabetic kidney disease earlier
and has enabled me to deploy the right care path, direct care
resources and provide treatment guidance based on my patients’ risk
level at the right time.”
Joseph Vassalotti, MD, FASN, Clinical
Professor of Medicine (Nephrology) at Icahn Mount Sinai and Chief
Medical Officer of the National Kidney Foundation, NYC,
NY: “13.1 % of the US population has diabetes, most with
type 2 diabetes, but about 40% also have low kidney function and/or
increased albumin, a type of protein, in the urine. Early risk
stratification for these patients with kidney disease informs their
care management. KidneyIntelX combines biomarkers and the data from
the patients’ health record, to produce a risk score that is easy
to understand. For patients, reviewing the results of that risk
score helps motivate them to take additional action toward their
kidney health that is proportional to the risk. As a nephrologist
it helps me think about the types of lifestyle modification,
patient engagement, medication management and interdisciplinary
care that is optimal for my patients.”
Katherine Tuttle, MD, FASN, FACP, FNKF,
Professor of Medicine in Nephrology at the University of
Washington, the Executive Director for Research at Providence
Health Care, and a Co-Principal Investigator at the Institute for
Translational Health Sciences: “KidneyIntelX leads into
more effective therapeutic management which should lead to improved
outcomes in a value-based system. For example, heart failure and
chronic kidney disease occur concomitantly. If we reduce heart
failure hospitalization by identifying and managing higher risk
patients more effectively, that would be a huge savings to the
health care system. If we also prevent cases of kidney failure, and
the costs associated with treating patients with kidney failure, we
will realize enormous cost savings. The triangulation between
diabetes, heart failure and chronic kidney disease accounts for one
third of the Medicare budget and this cost is extensive in the
veteran population as well.”
As the largest integrated health care network in
the United States, the U.S. Department of Veterans Affairs is
tasked with providing care to America’s Veterans. One in four
veterans have diabetes and many have comorbid conditions including
kidney disease. Renalytix is committed to promoting kidney health
in veterans by aligning care models that proactively protect
kidneys from avertable harm.
About Kidney DiseaseKidney
disease is now recognized as a public health epidemic affecting
over 850 million people globally. The Centers for Disease Control
and Prevention (CDC) estimates that 15% of US adults, or 37 million
people, currently have chronic kidney disease (CKD). Further, the
CDC reports that 9 out of 10 adults with CKD do not know they have
it and one out of two people with very low kidney function who are
not on dialysis do not know they have CKD.1 Kidney disease is
referred to as a “silent killer” because it often has no symptoms
and can go undetected until a very advanced stage. Each year kidney
disease kills more people than breast and prostate cancer. Every
day, 13 patients in the United States die while waiting for a
kidney transplant.
About KidneyIntelX
KidneyIntelX, is a first-of-kind solution that enables early-stage
diabetic kidney diseases (DKD) progression risk assessment by
combining diverse data inputs, including validated blood-based
biomarkers, inherited genetics, and personalized patient data from
electronic health record, or EHR, systems, and employs a
proprietary algorithm to generate a unique patient risk score. This
patient risk score enables prediction of progressive kidney
function decline in CKD, allowing physicians and healthcare systems
to optimize the allocation of treatments and clinical resources to
patients at highest risk.
About RenalytixRenalytix
(NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the
new field of bioprognosis™ for kidney health. The company has
engineered a new solution that successfully enables early-stage
chronic kidney disease, progression risk assessment. The Company’s
lead product, KidneyIntelX, has been granted Breakthrough
Designation by the U.S. Food and Drug Administration and is
designed to help make significant improvements in kidney disease
prognosis, transplant management, clinical care, patient
stratification for drug clinical trials, and drug target discovery
(visit www.kidneyintelx.com). For more information, visit
www.renalytix.com.
KidneyIntelX is based on technology developed by
Mount Sinai faculty and licensed to Renalytix, and is currently
utilized in sponsored research by Renalytix at Mount Sinai. Mount
Sinai and Mount Sinai faculty, including Dr. Steve Coca and Dr.
Girish Nadkarni, have a financial interest in Renalytix. Mount
Sinai has representation on the Renalytix Board of Directors.
Sources1 https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
Forward Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended.
Examples of these forward-looking statements include statements
concerning: the potential benefits, including economic savings, of
KidneyIntelX, the potential for KidneyIntelX to receive regulatory
approval from the FDA, the commercial prospects of KidneyIntelX, if
approved, including whether KidneyIntelX will be successfully
adopted by physicians and distributed and marketed, our
expectations regarding reimbursement decisions and the ability of
KidneyIntelX to curtail costs of chronic and end-stage kidney
disease, optimize care delivery and improve patient outcomes. Words
such as “anticipates,” “believes,” “estimates,” “expects,”
“intends,” “plans,” “seeks,” and similar expressions are intended
to identify forward-looking statements. We may not actually achieve
the plans and objectives disclosed in the forward-looking
statements, and you should not place undue reliance on our
forward-looking statements. Any forward-looking statements are
based on management's current views and assumptions and involve
risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. These risks and uncertainties include,
among others: that KidneyIntelX is based on novel artificial
intelligence technologies that are rapidly evolving and potential
acceptance, utility and clinical practice remains uncertain; we
have only recently commercially launched KidneyIntelX; and risks
relating to the impact on our business of the COVID-19 pandemic or
similar public health crises. These and other risks are described
more fully in our filings with the Securities and Exchange
Commission (SEC), including the “Risk Factors” section of our
annual report on Form 20-F filed with the SEC on October 21, 2021,
and other filings we make with the SEC from time to time. All
information in this press release is as of the date of the release,
and we undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise, except as required by law.
Media Contacts:United States:Jennifer
MoritzZer0 to 5ive for RenalytixAI(917)
748-4006jmoritz@0to5.com
Outside of the United States:Walbrook PR
Limited Paul McManus
/ Lianne CawthorneTel: 020 7933 8780 or
renalytix@walbrookpr.comMob: 07980 541 893 / 07584 391 303
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024